BlackRock’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-6,373,511
| Closed | -$120M | – | 5167 |
|
|
2019
Q3 | $120M | Sell |
6,373,511
-570,353
| -8% | -$6.52M | 0.01% | 1783 |
|
|
2019
Q2 | $81.7M | Buy |
6,943,864
+1,169,344
| +20% | +$14.2M | ﹤0.01% | 2033 |
|
|
2019
Q1 | $78.8M | Buy |
5,774,520
+839,896
| +17% | +$10.9M | ﹤0.01% | 2021 |
|
|
2018
Q4 | $50.6M | Buy |
4,934,624
+61,852
| +1% | +$792K | ﹤0.01% | 2238 |
|
|
2018
Q3 | $81.1M | Buy |
4,872,772
+54,794
| +1% | +$990K | ﹤0.01% | 2102 |
|
|
2018
Q2 | $76.1M | Sell |
4,817,978
-459,395
| -9% | -$6.98M | ﹤0.01% | 2112 |
|
|
2018
Q1 | $67M | Buy |
5,277,373
+300,710
| +6% | +$4.35M | ﹤0.01% | 2091 |
|
|
2017
Q4 | $57M | Sell |
4,976,663
-33,792
| -0.7% | -$377K | ﹤0.01% | 2204 |
|
|
2017
Q3 | $61.4M | Buy |
5,010,455
+1,173,419
| +31% | +$12.2M | ﹤0.01% | 2159 |
|
|
2017
Q2 | $43.9M | Sell |
3,837,036
-119,016
| -3% | -$2.2M | ﹤0.01% | 2337 |
|
|
2017
Q1 | $82.3M | Buy |
3,956,052
+3,937,541
| +21,271% | +$87.2M | ﹤0.01% | 1907 |
|
|
2016
Q4 | $385K | Buy |
18,511
+4,045
| +28% | +$105K | ﹤0.01% | 1806 |
|
|
2016
Q3 | $474K | Hold |
14,466
| – | – | ﹤0.01% | 1765 |
|
|
2016
Q2 | $361K | Sell |
14,466
-3,120
| -18% | -$84.4K | ﹤0.01% | 1812 |
|
|
2016
Q1 | $431K | Sell |
17,586
-54,925
| -76% | -$1.27M | ﹤0.01% | 1587 |
|
|
2015
Q4 | $2.4M | Sell |
72,511
-11,344
| -14% | -$384K | ﹤0.01% | 1022 |
|
|
2015
Q3 | $2.75M | Sell |
83,855
-29,100
| -26% | -$1.24M | ﹤0.01% | 941 |
|
|
2015
Q2 | $5.98M | Sell |
112,955
-4,247
| -4% | -$154K | 0.01% | 794 |
|
|
2015
Q1 | $3.38M | Buy |
117,202
+52,600
| +81% | +$1.44M | ﹤0.01% | 953 |
|
|
2014
Q4 | $1.88M | Buy |
64,602
+202
| +0.3% | +$3.63K | ﹤0.01% | 1069 |
|
|
2014
Q3 | $817K | Sell |
64,400
-4,500
| -7% | -$68K | ﹤0.01% | 1255 |
|
|
2014
Q2 | $1.38M | Buy |
+68,900
| New | +$970K | ﹤0.01% | 1129 |
|
BlackRock's ALDR Position: Q4 2019 in Review
BlackRock sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 6,373,511 shares — an estimated $120M sold.
BlackRock first reported a position in ALDR in Q2 2014 and held it in 22 quarters. The position peaked at $120M in Q3 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- BlackRock reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- BlackRock sold 6,373,511 Alder Biopharmaceuticals shares in Q4 2019, an estimated $120M.
- BlackRock first reported a position in Alder Biopharmaceuticals in Q2 2014 and held it in 22 quarters.
- BlackRock's Alder Biopharmaceuticals position peaked at $120M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on BlackRock's 13F filing for Q4 2019, filed 13 Feb 2020.